Comment
Author: Admin | 2025-04-28
Is post-CABG (AHA [Kulik 2015]) and:Age ≤75 years: High-intensity therapy: 20 to 40 mg once dailyAge >75 years: Moderate- to high-intensity therapy: 5 to 40 mg once daily (ACC/AHA [Grundy 2018]); if a moderate-intensity dose (5 to 10 mg once daily) is started and tolerated, increase to a high-intensity dose (20 to 40 mg once daily) within 3 months (Rosenson 2019).Not a candidate for high-intensity therapy: Moderate-intensity therapy: 5 to 10 mg once dailyUS Preventive Services Task Force recommendations (USPSTF 2016): Age 40 to 75 years, no history of CVD, with ≥1 CVD risk factor (dyslipidemia, diabetes, hypertension, or smoking), and calculated 10-year CVD event risk of ≥10%:Primary prevention: Moderate-intensity therapy: 5 to 10 mg once dailyNote: These recommendations do not pertain to patients with very high cholesterol levels (eg, LDL >190 mg/dL, familial hypercholesterolemia; were excluded from primary prevention trials); use clinical judgment in the treatment of these patients. In patients with a calculated 10-year CVD event risk of 7.5% to 10%, statin use may be considered based on patient characteristics.Dosage adjustment for rosuvastatin with concomitant medications: Oral:Cyclosporine: Rosuvastatin dose should not exceed 5 mg once dailyGemfibrozil: Avoid concurrent use; if unable to avoid concurrent use, initiate rosuvastatin at 5 mg once daily (maximum: 10 mg/day)Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Initiate rosuvastatin at 5 mg once daily (maximum: 10 mg/day).Dosage adjustment for hematuria and/or persistent, unexplained proteinuria while on 40 mg daily: Reduce dose and evaluate causes.Dosing: GeriatricRefer to adult dosing.Dosing: PediatricNote: Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more. A lower, conservative dosing regimen may be necessary in patient populations predisposed to myopathy, including patients of Asian descent or concurrently receiving other lipid-lowering agents (eg, gemfibrozil, niacin, fibric
Add Comment